WO2019214757A1 - Proteínas de fusión compuestas por una muteina de interleucina-2 e interferon tipo 1 - Google Patents
Proteínas de fusión compuestas por una muteina de interleucina-2 e interferon tipo 1 Download PDFInfo
- Publication number
- WO2019214757A1 WO2019214757A1 PCT/CU2019/050003 CU2019050003W WO2019214757A1 WO 2019214757 A1 WO2019214757 A1 WO 2019214757A1 CU 2019050003 W CU2019050003 W CU 2019050003W WO 2019214757 A1 WO2019214757 A1 WO 2019214757A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- fusion protein
- mutein
- cells
- ifna
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/052,912 US11926654B2 (en) | 2018-05-07 | 2019-03-05 | Fusion proteins composed of an interleukin-2 mutein and type I interferon |
JP2021512997A JP7423607B2 (ja) | 2018-05-07 | 2019-05-03 | インターロイキン 2突然変異タンパク質およびi型インターフェロンで構成される融合タンパク質 |
BR112020022511-8A BR112020022511A2 (pt) | 2018-05-07 | 2019-05-03 | proteínas de fusão compostas por uma muteína de interleucina-2 (il-2) e interferon do tipo i |
CN201980031020.6A CN112218884A (zh) | 2018-05-07 | 2019-05-03 | 由白介素-2突变蛋白和i型干扰素构成的融合蛋白 |
CA3098653A CA3098653A1 (en) | 2018-05-07 | 2019-05-03 | Fusion proteins composed of an interleukin-2 mutein and type i interferon |
EP19729611.4A EP3792277A1 (en) | 2018-05-07 | 2019-05-03 | Fusion proteins composed of an interleukin-2 mutein and type i interferon |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU2018000039A CU24554B1 (es) | 2018-05-07 | 2018-05-07 | Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1 |
CU2018-000039 | 2018-05-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019214757A1 true WO2019214757A1 (es) | 2019-11-14 |
Family
ID=68467792
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CU2019/050003 WO2019214757A1 (es) | 2018-05-07 | 2019-05-03 | Proteínas de fusión compuestas por una muteina de interleucina-2 e interferon tipo 1 |
Country Status (10)
Country | Link |
---|---|
US (1) | US11926654B2 (es) |
EP (1) | EP3792277A1 (es) |
JP (1) | JP7423607B2 (es) |
CN (1) | CN112218884A (es) |
AR (1) | AR115083A1 (es) |
BR (1) | BR112020022511A2 (es) |
CA (1) | CA3098653A1 (es) |
CU (1) | CU24554B1 (es) |
TW (1) | TWI821287B (es) |
WO (1) | WO2019214757A1 (es) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021127495A1 (en) * | 2019-12-20 | 2021-06-24 | Regeneron Pharmaceuticals, Inc. | Novel il2 agonists and methods of use thereof |
US11053294B2 (en) | 2018-09-27 | 2021-07-06 | Xilio Development, Inc. | Masked cytokine polypeptides |
US11352403B2 (en) | 2018-05-14 | 2022-06-07 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
US11453710B2 (en) | 2018-05-14 | 2022-09-27 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
US11739132B2 (en) | 2019-05-14 | 2023-08-29 | Werewolf Therapeutics, Inc. | Separation moieties and methods of use thereof |
US11896648B2 (en) | 2020-10-22 | 2024-02-13 | Gilead Sciences, Inc. | Interleukin-2 variant proteins fused to human IgG4 Fc and uses thereof |
US11981716B2 (en) | 2021-05-14 | 2024-05-14 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230303650A1 (en) * | 2022-01-21 | 2023-09-28 | Aetio Biotherapy, Inc. | Immunoconjugates of Interlukin-2 Mutant Polypeptides with Antibodies |
CN114853909A (zh) * | 2022-05-13 | 2022-08-05 | 南京吉盛澳玛生物医药有限公司 | 新型IL-2与INFα和Fc融合蛋白的设计、制备及用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005001025A2 (en) * | 2003-05-06 | 2005-01-06 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
US20110150828A1 (en) | 2008-06-20 | 2011-06-23 | Jacques Galipeau | Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof |
US9206243B2 (en) | 2010-11-12 | 2015-12-08 | Centro De Immunologia Molecular | IL-2 derivative polypeptides |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6610830B1 (en) * | 1980-07-01 | 2003-08-26 | Hoffman-La Roche Inc. | Microbial production of mature human leukocyte interferons |
DK1187852T3 (da) | 1999-05-19 | 2007-11-26 | Merck Patent Gmbh | Ekspression og eksport af interferon-alpha-proteiner som Fc-fusionsproteiner |
MXPA02001417A (es) | 1999-08-09 | 2002-08-12 | Lexigen Pharm Corp | Complejos multiples de citosina-anticuerpo. |
CN102041263B (zh) | 2010-02-08 | 2013-01-09 | 河南省动物疫病预防控制中心 | 鸡α干扰素/白细胞介素2嵌合基因 |
US9428567B2 (en) | 2010-12-22 | 2016-08-30 | The Board Of Trustees Of The Leland Stanford Junior University | Antagonists of interleukin-2 receptor |
TW201315742A (zh) * | 2011-09-26 | 2013-04-16 | Novartis Ag | 治療代謝病症之雙功能蛋白質 |
WO2014100014A1 (en) * | 2012-12-17 | 2014-06-26 | The Board Of Trustees Of The Leland Stanford Junior University | Super-2 complexes with antibody to augment il-2 therapy |
CN104877029A (zh) * | 2015-04-24 | 2015-09-02 | 昆明理工大学 | 一种Vimentin-Fc融合蛋白及其应用 |
CN106397607A (zh) * | 2016-09-13 | 2017-02-15 | 河南师范大学 | 重组人成纤维细胞生长因子21融合蛋白及其在制备治疗代谢疾病药物中的应用 |
CN107245108A (zh) | 2017-08-09 | 2017-10-13 | 芜湖英特菲尔生物制品产业研究院有限公司 | 牛白蛋白‑干扰素α‑白介素2融合蛋白、制备方法及其编码基因、一种牛长效干扰素 |
CN107286254A (zh) | 2017-08-09 | 2017-10-24 | 芜湖英特菲尔生物制品产业研究院有限公司 | 犬白蛋白‑干扰素α‑白介素2融合蛋白、制备方法及其编码基因、一种犬长效干扰素 |
-
2018
- 2018-05-07 CU CU2018000039A patent/CU24554B1/es unknown
-
2019
- 2019-03-05 US US17/052,912 patent/US11926654B2/en active Active
- 2019-05-03 JP JP2021512997A patent/JP7423607B2/ja active Active
- 2019-05-03 CN CN201980031020.6A patent/CN112218884A/zh active Pending
- 2019-05-03 BR BR112020022511-8A patent/BR112020022511A2/pt unknown
- 2019-05-03 WO PCT/CU2019/050003 patent/WO2019214757A1/es unknown
- 2019-05-03 CA CA3098653A patent/CA3098653A1/en active Pending
- 2019-05-03 EP EP19729611.4A patent/EP3792277A1/en active Pending
- 2019-05-06 TW TW108115578A patent/TWI821287B/zh active
- 2019-05-07 AR ARP190101204A patent/AR115083A1/es unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005001025A2 (en) * | 2003-05-06 | 2005-01-06 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
US20110150828A1 (en) | 2008-06-20 | 2011-06-23 | Jacques Galipeau | Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof |
US9206243B2 (en) | 2010-11-12 | 2015-12-08 | Centro De Immunologia Molecular | IL-2 derivative polypeptides |
Non-Patent Citations (17)
Title |
---|
ACRES B., CANCER RESEARCH, vol. 65, 2005, pages 9536 - 9546 |
ARON M. LEVIN ET AL: "Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'", NATURE, vol. 484, no. 7395, 25 March 2012 (2012-03-25), pages 529 - 533, XP055214333, ISSN: 0028-0836, DOI: 10.1038/nature10975 * |
BECKER J.C., PNAS, vol. 93, 1996, pages 2702 - 2707 |
CARMENATE, THE JOURNAL OF IMMUNOLOGY, vol. 190, 2013, pages 6230 - 6238 |
CHAPUT, J IMMUNOL, vol. 179, 2007, pages 4969 - 4978 |
CHIKKALA, CANCER RESEARCH, vol. 50, 1990, pages 1176 - 1182 |
DIMITRI FLIEGER ET AL: "COMBINATIONS OF THE CYTOKINES IL-12, IL-2 AND IFN-[alpha] SIGNIFICANTLY AUGMENT WHEREAS THE CYTOKINE IL-4 SUPPRESSES THE CYTOKINE-INDUCED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY OF MONOCLONAL ANTIBODIES 17-1A AND BR55-2", CYTOKINE, vol. 12, no. 6, 1 June 2000 (2000-06-01), US, pages 756 - 761, XP055602099, ISSN: 1043-4666, DOI: 10.1006/cyto.1999.0610 * |
DONDI, THE JOURNAL OF IMMUNOLOGY, vol. 173, no. 6, 2004, pages 3740 - 3747 |
HE P ET AL: "The targeted expression of the human interleukin-2/interferon alpha2b fused gene in alpha-fetoprotein-expressing hepatocellular carcinoma cells.", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 1999, vol. 125, no. 2, 1999, pages 77 - 82, XP009514290, ISSN: 0171-5216 * |
HE, J LEUKOC BIOL, vol. 125, 1999, pages 77 - 82 |
HEZAREH, J VIROL., vol. 75, no. 24, 2001, pages 12161 - 12168 |
KONJEVIC, MELANOMA RESEARCH, vol. 20, 2010, pages 459 - 67 |
LEVIN, NATURE, vol. 48, 2012, pages 529 - 535 |
OVENSNAUGLER, THEORETICAL BIOLOGY AND MEDICAL MODELLING, vol. 9, 2012, pages 44 |
SONJA STEPPAN ET AL: "Reduced Secondary Cytokine Induction by BAY 50-4798, a High-Affinity Receptor-Specific Interleukin-2 Analog", JOURNAL OF INTERFERON AND CYTOKINE RESEARCH., vol. 26, no. 3, 1 March 2006 (2006-03-01), US, pages 171 - 178, XP055602070, ISSN: 1079-9907, DOI: 10.1089/jir.2006.26.171 * |
STAGG J., CANCER RESEARCH, vol. 64, 2004, pages 8795 - 8799 |
VAN DER JEUGHT, ONCOLMMUNOLOGY, vol. 4, 2015, pages 5 |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11453710B2 (en) | 2018-05-14 | 2022-09-27 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
US11535658B2 (en) | 2018-05-14 | 2022-12-27 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
US11352403B2 (en) | 2018-05-14 | 2022-06-07 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
US11718655B2 (en) | 2018-09-27 | 2023-08-08 | Xilio Development, Inc. | Masked interleukin-12 polypeptides |
US11053294B2 (en) | 2018-09-27 | 2021-07-06 | Xilio Development, Inc. | Masked cytokine polypeptides |
US11827686B2 (en) | 2018-09-27 | 2023-11-28 | Xilio Development, Inc. | Masked cytokine polypeptides |
US11827685B2 (en) | 2018-09-27 | 2023-11-28 | Xilio Development, Inc. | Masked cytokine polypeptides |
US11866476B2 (en) | 2018-09-27 | 2024-01-09 | Xilio Development, Inc. | Masked IL-2-Fc fusion polypeptides |
US11739132B2 (en) | 2019-05-14 | 2023-08-29 | Werewolf Therapeutics, Inc. | Separation moieties and methods of use thereof |
US20220362395A1 (en) * | 2019-12-20 | 2022-11-17 | Regeneron Pharmaceuticals, Inc. | Novel il2 agonists and methods of use thereof |
WO2021127495A1 (en) * | 2019-12-20 | 2021-06-24 | Regeneron Pharmaceuticals, Inc. | Novel il2 agonists and methods of use thereof |
US11725034B2 (en) | 2019-12-20 | 2023-08-15 | Regeneron Pharmaceuticals, Inc. | IL2 agonists and methods of use thereof |
US11896648B2 (en) | 2020-10-22 | 2024-02-13 | Gilead Sciences, Inc. | Interleukin-2 variant proteins fused to human IgG4 Fc and uses thereof |
US11981716B2 (en) | 2021-05-14 | 2024-05-14 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
Also Published As
Publication number | Publication date |
---|---|
CN112218884A (zh) | 2021-01-12 |
US11926654B2 (en) | 2024-03-12 |
JP2021522861A (ja) | 2021-09-02 |
TW202014431A (zh) | 2020-04-16 |
CU24554B1 (es) | 2021-11-04 |
BR112020022511A2 (pt) | 2021-02-09 |
CA3098653A1 (en) | 2019-11-14 |
AR115083A1 (es) | 2020-11-25 |
TWI821287B (zh) | 2023-11-11 |
US20210238246A1 (en) | 2021-08-05 |
CU20180039A7 (es) | 2019-12-03 |
EP3792277A1 (en) | 2021-03-17 |
JP7423607B2 (ja) | 2024-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019214757A1 (es) | Proteínas de fusión compuestas por una muteina de interleucina-2 e interferon tipo 1 | |
US11096989B2 (en) | Synergistic tumor treatment with an extended pharmacokinetic IL-2 and integrin-binding-Fc fusion protein | |
US20200283498A1 (en) | T cell receptor fusions and conjugates and methods of use thereof | |
TWI714544B (zh) | 白細胞介素15蛋白質複合物及其用途 | |
Han et al. | IL-15: IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization | |
JP6660297B2 (ja) | 疾患及び障害を処置するためのインターロイキン−10の使用方法 | |
KR101559330B1 (ko) | 암 및 만성 감염 치료를 위한, 효능제 활성을 갖는 인터루킨 2로부터 유도된 폴리펩티드 | |
ES2322936T3 (es) | Modulacion de las respuestas de las celulas t mediadas por il-2 y por il-15. | |
CN110396133B (zh) | 一种以白介素12为活性成分的融合蛋白型药物前体 | |
Sadun et al. | Fc-mOX40L fusion protein produces complete remission and enhanced survival in 2 murine tumor models | |
KR20240004453A (ko) | 변형된 과립구 집락-자극 인자(g-csf) 및 이에 결합하는 키메라 사이토카인 수용체 | |
US20210008167A1 (en) | T cell receptor fusions and conjugates and methods of use thereof | |
JP2022525921A (ja) | 免疫エフェクタ細胞の特異的活性化のためのインターロイキン2受容体(il2r)およびインターロイキン2(il2)バリアント | |
Ren et al. | Facts and hopes on chimeric cytokine agents for cancer immunotherapy | |
WO2023143308A1 (zh) | 一种pd1抗体与白介素2融合的双功能分子 | |
CN107098964A (zh) | 一种肿瘤特异性重组水蛭素及其制备方法和用途 | |
Silver et al. | An engineered immunocytokine with collagen affinity improves the tumor bioavailability, tolerability, and therapeutic efficacy of IL-2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19729611 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3098653 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2021512997 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112020022511 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2019729611 Country of ref document: EP Effective date: 20201207 |
|
ENP | Entry into the national phase |
Ref document number: 112020022511 Country of ref document: BR Kind code of ref document: A2 Effective date: 20201104 |